HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target

Kelley, 2003, Gastric cancer epidemiology and risk factors, J Clin Epidemiol, 56, 1, 10.1016/S0895-4356(02)00534-6

Montgomery, 2001, Dysplasia as a predictive marker for invasive carcinoma in Barrett's esophagus. A follow-up study based on 138 cases from a diagnostic variability study, Hum Pathol, 32, 379, 10.1053/hupa.2001.23511

Correa, 1996, Helicobacter pylori and gastric cancer: state of the art, Cancer Epidemiol Biomarkers Prev, 5, 477

Cunningham, 2006, Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer, New Eng J Med, 355, 11, 10.1056/NEJMoa055531

Macdonald, 2001, Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction, N Eng J Med, 345, 725, 10.1056/NEJMoa010187

Sastre, 2006, Chemotherapy for gastric cancer, World J Gastroenterol, 12, 2004, 10.3748/wjg.v12.i2.204

Wagner, 2006, Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data, J Clin Oncol, 24, 2903, 10.1200/JCO.2005.05.0245

Akiyama, 1986, The product of the human c-erbB–2 gene: a 185-kilo-Dalton glycoprotein with tyrosine kinase activity, Science, 232, 1644, 10.1126/science.3012781

Coussens, 1985, Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene, Science, 230, 1132, 10.1126/science.2999974

Slamon, 1989, Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, Science, 244, 707, 10.1126/science.2470152

Kaptain, 2001, Her–2/neu and breast cancer, Diagn Mol Pathol, 10, 139, 10.1097/00019606-200109000-00001

Schuell, 2006, HER 2/neu protein expression in colorectal cancer, BMC Cancer, 8, 123, 10.1186/1471-2407-6-123

Eltze, 2005, Cox-2 and Her2/neu co-expression in invasive bladder cancer, Int J Oncol, 26, 1525

McKenzie, 1993, Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer, Cancer, 71, 3942, 10.1002/1097-0142(19930615)71:12<3942::AID-CNCR2820711224>3.0.CO;2-3

Hetzel, 1992, HER-2/neu expression: a major prognostic factor in endometrial cancer, Gynecol Oncol, 47, 179, 10.1016/0090-8258(92)90103-P

Hirashima, 2001, Protein overexpression and gene amplification of c-erb B-2 in pulmonary carcinomas: a comparative immunohistochemical and fluorescence in situ hybridization study, Mod Pathol, 14, 556, 10.1038/modpathol.3880350

Mitra, 1994, ERBB2 (HER2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix, Cancer Res, 54, 637

Beckhardt, 1995, HER-2/neu oncogene characterization in head and neck squamous cell carcinoma, Arch Otolaryngol Head Neck Surg, 121, 1265, 10.1001/archotol.1995.01890110041008

Reichelt, 2007, Frequent homogenous HER-2 amplification in primary and metastatic adenocarcinomas of the esophagus, Mod Path, 20, 120, 10.1038/modpathol.3800712

Smith, 2007, 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial, Lancet, 369, 29, 10.1016/S0140-6736(07)60028-2

Slamon, 2001, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med, 344, 783, 10.1056/NEJM200103153441101

Scartozzi, 2004, Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches, Cancer Treat Rev, 30, 451, 10.1016/j.ctrv.2004.01.001

Sakai, 1986, Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas, J Natl Cancer Inst, 77, 1047

Yonemura, 1991, Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short-term prognosis in gastric cancer, Cancer Res, 51, 1034

Ishida, 1994, Significance of erbB-2 gene product as a target molecule for cancer therapy, Scand J Immunol, 39, 459, 10.1111/j.1365-3083.1994.tb03401.x

Tokunaga, 1995, Clinical significance of epidermal growth factor (EGF), EGF receptor and c-erbB-2 in human gastric cancer, Cancer, 75, 1418, 10.1002/1097-0142(19950315)75:6+<1418::AID-CNCR2820751505>3.0.CO;2-Y

Yano, 2004, Expression of HER2 in gastric cancer: comparison between protein expression and gene amplification using a new commercial kit, J Clin Oncol, 22, 14S, 10.1200/jco.2004.22.90140.4053

Gravalos, 2007, Correlation between Her2/neu overexpression/amplification and clinicopathological parameters in advanced gastric cancer patients: a prospective study

Allgayer, 2000, C-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor associated protease systems, J Clin Oncol, 18, 2201, 10.1200/JCO.2000.18.11.2201

Park, 2006, HER-2/neu amplification is an independent prognostic factor in gastric cancer, Dig Dis Sci, 51, 1371, 10.1007/s10620-005-9057-1

Lordick, 2007, HER2-positive advanced gastric cancer: similar HER2-positivity levels to breast cancer, Eur J Cancer, 5, 271

Kang, 2008, Incidence of gastric and gastro-esophageal cancer in the ToGA trial: correlation with HER2 positivity

Tateishi, 1992, Clinicopathological significance of c-erbB-2 protein expression in human gastric carcinoma, Surg Oncol, 49, 209, 10.1002/jso.2930490402

Sasano, 1993, Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells, Hum Pathol, 24, 584, 10.1016/0046-8177(93)90236-A

Uchino, 1993, Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients, Cancer, 72, 3179, 10.1002/1097-0142(19931201)72:11<3179::AID-CNCR2820721108>3.0.CO;2-#

Mizutani, 1993, Relationship of c-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer, Cancer, 72, 2083, 10.1002/1097-0142(19931001)72:7<2083::AID-CNCR2820720705>3.0.CO;2-1

Nakajima, 1999, The prognostic significance of amplification and overexpression of c-met and c-erbB-2 in human gastric carcinomas, Cancer, 85, 1894, 10.1002/(SICI)1097-0142(19990501)85:9<1894::AID-CNCR3>3.0.CO;2-J

Garcia, 2003, Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer, Ann Surg Oncol, 10, 234, 10.1245/ASO.2003.05.010

Tanner, 2005, Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab, Ann Oncol, 16, 273, 10.1093/annonc/mdi064

Takehana, 2002, Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay, Int J Cancer, 98, 833, 10.1002/ijc.10257

Lin, 1995, Occurrence of microsatellite instability in gastric carcinoma is associated with enhanced expression of erbB-2 oncoprotein, Cancer Res, 55, 1428

Wu, 1997, Genetic alterations in gastric cancer: relation to histological subtypes, tumor stage, and Helicobacter pylori infection, Gastroenterology, 112, 1457, 10.1016/S0016-5085(97)70071-4

Polkowski, 1999, Prognostic value of Lauren's classification and c-erbB-2 oncogene overexpression in adenocarcinoma of the esophagus and gastroesophageal junction, Ann Surg Oncol, 6, 290, 10.1007/s10434-999-0290-2

Lemoine, 1991, Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer, Br J Cancer, 64, 79, 10.1038/bjc.1991.243

Hochwald, 2000, Analysis of 154 actual five-year survivors of gastric cancer, J Gastrointest Surg, 4, 520, 10.1016/S1091-255X(00)80095-5

Berx, 1998, Mutations of the human E-cadherin (CDH1) gene, Hum Mutat, 12, 226, 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D

Becker, 2000, The use of molecular biology in diagnosis and prognosis of gastric cancer, Surg Oncol, 9, 5, 10.1016/S0960-7404(00)00016-5

Pedrazzani, 2007, E-cadherin and hereditary diffuse gastric cancer, Surgery, 142, 645, 10.1016/j.surg.2007.06.006

Pauletti, 1996, Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization, Oncogene, 13, 63

Schnitt, 2001, Breast cancer in the 21st century: new opportunities and new challenges, Mod Pathol, 14, 213, 10.1038/modpathol.3880288

Kameda, 1990, Expression of ERBB2 in human gastric carcinomas: relationship between p185ERBB2 expression and the gene amplification, Cancer Res, 50, 8002

Hollywood, 1993, A novel transcription factor, OB2-1, is required for overexpression of the proto-oncogene c-erbB-2 in mammary tumour lines, EMBO J, 12, 2369, 10.1002/j.1460-2075.1993.tb05891.x

Hofmann, 2006, HER2 status evaluation for gastric cancer: a consensus study

Sliwkowski, 1999, Non clinical studies addressing the mechanism of action of trastuzumab (Herceptin), Semin Oncol, 26, 60

Cuello, 2001, Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2, Cancer Res, 61, 4892

Matsui, 2005, Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model, Int J Oncol, 27, 681

Fujimoto-Ouchi, 2007, Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models, Cancer Chemother Pharmacol, 59, 795, 10.1007/s00280-006-0337-z

Cortés-Funes, 2007, Phase II of trastuzumab and cisplatin in patients with advanced gastric cancer with HER2/neu overexpression/amplification, J Clin Oncol, 15, 18S

Nicholas, 2006, Early results of a trial of trastuzumab, cisplatin and docetaxel for the treatment of metastatic gastric cancer overexpressing HER-2, ESMO, 17, 316

Rech, 2006, A pilot study of trastuzumab monotherapy in patients who progressed while on chemotherapy for metastatic or locally advanced HER-2 positive gastric cancer, ESMO, 17, 314